{"id":798923,"date":"2025-01-08T08:34:24","date_gmt":"2025-01-08T13:34:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/"},"modified":"2025-01-08T08:34:24","modified_gmt":"2025-01-08T13:34:24","slug":"alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/","title":{"rendered":"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China"},"content":{"rendered":"

<\/p>\n

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China<\/b><\/p>\n

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE<\/a>)–
\nAlpha Cognition, Inc. (Nasdaq: ACOG) (\u201cACI\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings Limited (CMS) (867.HK), a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability in the People\u2019s Republic of China, today announced an exclusive licensing agreement for the development, manufacturing and commercialization of ZUNVEYL (benzgalantamine) in Asia (excluding Japan), Australia and New Zealand. ZUNVEYL is a next generation acetylcholinesterase inhibitor approved in the US for the treatment of mild-to-moderate Alzheimer\u2019s disease.<\/p>\n

\nTerms of the agreement total $44 million, which includes $6 million in total upfront payments split into tranches and development and commercial milestone payments. Additionally, ACI is eligible to receive royalties on net sales of ZUNVEYL in Asia (excluding Japan), Australia and New Zealand. CMS will be responsible for the regulatory, development, manufacturing, and commercialization of ZUNVEYL in the licensed territories.<\/p>\n

\n\u201cWe are excited to partner with CMS to distribute ZUNVEYL, an FDA-approved oral treatment for mild-to-moderate Alzheimer\u2019s disease. The product has significant potential in China and we believe that CMS has the commitment and expertise to manage the complex regulatory and commercial landscape in these territories,\u201d said Michael McFadden, CEO of Alpha Cognition. \u201cWith their strong track record of developing and commercializing CNS therapies in China, we believe CMS is the ideal partner to advance ZUNVEY\u2019s regulatory development in a region where 50 million people are estimated to have Alzheimer\u2019s disease.\u201d<\/p>\n

\nAlpha Cognition remains on track to launch ZUNVEYL in the United States in Q1 2025. The company will provide a corporate update and present its Launch Strategy on January 28, 2025 at 4pm EST.<\/p>\n

About CMS<\/b><\/p>\n

\nCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global FIC and BIC innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products. CMS deeply engages in several specialty therapeutic fields, such as cardio-cerebrovascular, central nervous system, gastroenterology, dermatology and ophthalmology, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. For more information about CMS, please visit https:\/\/web.cms.net.cn\/en\/home<\/a>.<\/p>\n

About Alpha Cognition Inc.<\/b><\/p>\n

\nAlpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer\u2019s disease and Cognitive Impairment with mild Traumatic Brain Injury (\u201cmTBI\u201d), for which there are currently no approved treatment options.<\/p>\n

\nZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease, with expected minimal gastrointestinal side effects. ZUNVEYL\u2019s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer\u2019s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.<\/p>\n

\nForward-looking Statements<\/p>\n

\nThis news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward\u2010looking statement that reflects the Company\u2019s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward\u2010looking statements by the words \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cobjective,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201cseek,\u201d \u201ccontemplate,\u201d \u201ccontinue\u201d and \u201congoing,\u201d or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward\u2010looking statements may include statements regarding the potential benefits of the licensing agreement for the development and commercialization of ZUNVEYL in Asia (excluding Japan), Australia and New Zealand, the Company\u2019s timing and planned activities to launch ZUNVEYL in the U.S. and China, the timing for the Company\u2019s planned corporate update call, the potential timing for the availability of ZUNVEYL in the U.S. and China, the potential future developments of ZUNVEYL in China, the potential market size for ZUNVEYL in China, the Company\u2019s business strategy for the launch of ZUNVEYL in China, the market size and demand for ZUNVEYL in China, the Company\u2019s potential growth opportunities in China, the timing and results of the Company\u2019s milestone payments for China, the Company\u2019s regulatory submissions in China, and the potential regulatory approval and commercialization of the Company\u2019s products in China. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company\u2019s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company\u2019s filings with Canadian securities regulatory authorities and available at www.sedar.com<\/a> and the Company\u2019s filings with the United States Securities and Exchange Commission (the \u201cSEC\u201d), including those risk factors under the heading \u201cRisk Factors\u201d in the Company\u2019s Form S-1\/A registration statement as filed with the SEC on November 6, 2024 and available at www.sec.gov<\/a>. These forward\u2010looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward\u2010looking statements for any reason, even if new information becomes available in the future, except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250108752271\/en\/<\/a><\/span><\/p>\n

\nFor further information:
\n
Investor Relations
\n
IR@alphacognition.com
\n<\/a>
https:\/\/www.alphacognition.com\/<\/a><\/p>\n

KEYWORDS:<\/b> North America United States Asia Pacific China Canada Texas<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Neurology Mental Health Health Pharmaceutical<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)– Alpha Cognition, Inc. (Nasdaq: ACOG) (\u201cACI\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings Limited (CMS) (867.HK), a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability in the People\u2019s Republic of China, today announced an exclusive licensing agreement for the development, manufacturing and commercialization of ZUNVEYL (benzgalantamine) in Asia (excluding Japan), Australia and New Zealand. ZUNVEYL is a next generation acetylcholinesterase inhibitor approved in the US for the treatment of mild-to-moderate Alzheimer\u2019s disease. … <\/p>\n

Continue reading “Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798923","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAlpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)– Alpha Cognition, Inc. (Nasdaq: ACOG) (\u201cACI\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings Limited (CMS) (867.HK), a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability in the People\u2019s Republic of China, today announced an exclusive licensing agreement for the development, manufacturing and commercialization of ZUNVEYL (benzgalantamine) in Asia (excluding Japan), Australia and New Zealand. ZUNVEYL is a next generation acetylcholinesterase inhibitor approved in the US for the treatment of mild-to-moderate Alzheimer\u2019s disease. … Continue reading "Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T13:34:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250108752271r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China\",\"datePublished\":\"2025-01-08T13:34:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/\"},\"wordCount\":1146,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250108752271r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/\",\"name\":\"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250108752271r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-01-08T13:34:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250108752271r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250108752271r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/","og_locale":"en_US","og_type":"article","og_title":"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China - Market Newsdesk","og_description":"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)– Alpha Cognition, Inc. (Nasdaq: ACOG) (\u201cACI\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings Limited (CMS) (867.HK), a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability in the People\u2019s Republic of China, today announced an exclusive licensing agreement for the development, manufacturing and commercialization of ZUNVEYL (benzgalantamine) in Asia (excluding Japan), Australia and New Zealand. ZUNVEYL is a next generation acetylcholinesterase inhibitor approved in the US for the treatment of mild-to-moderate Alzheimer\u2019s disease. … Continue reading \"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-08T13:34:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250108752271r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China","datePublished":"2025-01-08T13:34:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/"},"wordCount":1146,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250108752271r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/","name":"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250108752271r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-01-08T13:34:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250108752271r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250108752271r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-a-44-million-exclusive-licensing-agreement-for-the-development-and-commercialization-of-zunveyl-benzgalantamine-an-fda-approved-treatment-for-mild-to-moderate-alzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer\u2019s Disease, in China"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798923"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798923\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798923"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798923"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}